Genetic Foresight

About:

Genetic Foresight is personalizing medicine to enable safer and more effective prescriptions.

Website: http://www.geneticforesight.com

Twitter/X: geneforesight

Top Investors: Polaris Partners, SkyDeck Berkeley

Description:

Genetic Foresight’s mission is to prevent adverse drug reactions, increase therapeutic success rates, and minimize healthcare costs by enabling clinicians to make informed decisions. Founded in 2016, Genetic Foresight provides a genetic test that sequences targeted segments of patients' genomes as well as a comprehensive prescription decision platform that incorporates drug-genome, drug-drug, drug-disease, personal health, lifestyle, and medical and family histories to predict drug response. This allows the clinician to more safely and effectively prescribe medication based on the patient. The report is updated based on newly generated research, newly created drugs, and newly prescribed drugs, making it a lifetime test.

Total Funding Amount:

$17.6M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Berkeley, California, United States

Founded Date:

2016-12-15

Contact Email:

contact(AT)geneticforesight.com

Founders:

Douglas Hapeman, Matthew Milford

Number of Employees:

11-50

Last Funding Date:

2020-08-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai